Apr 6, 2011 | Digital Pathology, Laboratory News, Laboratory Pathology
Goal is to map genetic, transcriptomic, and epigenomic changes in various cancer types
Surgical pathologists are likely to gain great benefit from a worldwide research collaboration that has $500 million in funding, and whose participants plan to identify and publish data about the genetic complexities involved in at least 50 different types of tumors. It is a research project that will directly contribute to the development of new and more precise clinical laboratory tests.
This research is being conducted by geneticists from around the globe. They are collaborating to describe the genomic, the transcriptomic, and the epigenomic changes in 50 tumor types. Expectations are that this research will produce an unprecedented leap in knowledge and launch a new age in cancer research.
(more…)
Oct 22, 2010 | Laboratory News, Laboratory Pathology, News From Dark Daily
GE’s Acquisition Considered A Sign Of More Deals To Come In The Clinical Laboratory Industry
Here’s more confirmation that anatomic pathology continues to be a big target on the radar screen of big healthcare corporations and Wall Street investors. Today, GE Healthcare, a unit of General Electric Company (NYSE: GE), disclosed it will pay $587 million to acquire Clarient, Inc. (NASDAQ: CLRT), the medical testing laboratory.
For pathologists and clinical laboratory managers, this is further confirmation that GE—one of the world’s major players in molecular imagin and radiology—intends to combine molecular diagnostic technologies used in anatomic pathology with its molecular imaging technologies used in radiology. In the press release about the acquisition, GE wrote that the addition of Clairent would help it create “new integrated tools for the diagnosis and characterization of cancer.”
(more…)
May 3, 2010 | Laboratory News, Laboratory Pathology
Pathologists already find it difficult to obtain gene patent licenses needed to offer multi-gene molecular diagnostic tests
Patents on human genes are a major issue in pathology and clinical laboratory testing. Now a new report based on the study of the positive and negative consequences of gene patenting comes to the conclusion that patents on human genes tend to deter competition in the gene testing market more than they encourage further development of new technologies for measuring the risk of disease.
Medical science is on the brink of mainstreaming genetic discovery into patient care. But patents and exclusive licensing threaten to fragment ownership of the human genome and derail the promise of personalized medicine for everyone, observed James P. Evans, M.D., Ph.D., Clinical Professor of Genetics at the University of North Carolina-Chapel Hill, in his commentary on a new report from Duke University that focused on the impact of patenting and exclusive licensing of human genes.
(more…)
Apr 12, 2010 | Laboratory Pathology, Management & Operations, News From Dark Daily
Pathologists and clinical lab executives will hear perspectives from 80 speakers at the upcoming Executive War College on Lab and Pathology Management
For any pathologist or clinical laboratory executive interested in the future of the lab testing industry, there will be plenty of insights at the upcoming 15th Annual Executive War College on Laboratory and Pathology Management April 27-28 at the New Orleans Sheraton Hotel. Leading a line-up of 80 speakers are David King, CEO of Laboratory Corporation of America (NYSE: LH) and Thomas Grogan, M.D., Founder and Chief Scientific Advisor of Roche Ventana Medical Systems.
There’s lots of optimism about the future of laboratory testing. That’s because genetic and molecular testing is giving pathologists new tools to more precisely diagnose disease and determine appropriate therapies. LabCorp’s David King, will speak to how lab test data is the linchpin in the drive to more tightly integrate clinical care in ways to lift patient outcomes.
(more…)
